1. 3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067). (September 2015) Authors: Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J.J.; Cowey, C.L.; Lao, C.D.; Wagstaff, J.; Hogg, D.; Hill, A.; Carlino, M.S.; Wolter, P.; Lebbé, C.; Schachter, J.; Thomas, L.; Hassel, J.C.; Lorigan, P.; Walker, D.; Jiang, J.; Hodi, F.S.; Wolchok, J.D. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S664 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3338 Initial safety results from a multinational, prospective, observational study in advanced melanoma (MEL) (IMAGE). (September 2015) Authors: Middleton, M.; Dalle, S.; Corrie, P.; Loquai, C.; Terheyden, P.; Kähler, K.C.; Meiss, F.; Board, R.; Arance, A.M.; Gutzmer, R.; Tarhini, A.; Dummer, R.; Ernst, S.; Richtig, E.; Wolter, P.; Bulger, K.; Kotapati, S.; Le, T.K.; Brokaw, J.; Abernethy, A.P. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S678 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 3345 COMBI-v: health-related quality of life (HRQoL) impact of the combination of dabrafenib and trametinib (D+T) vs vemurafenib (V) in patients with BRAF V600 metastatic melanoma (MM). (September 2015) Authors: Grob, J.J.; Amonkar, M.; Karaszewska, B.; Schachter, J.; Dummer, R.; Mackiewicz, A.; Stroiakovski, D.; Drucis, K.; Grange, F.; Chiarion-Sileni, V.; Rutkowski, P.; Lichinitser, M.; Levchenko, E.; Wolter, P.; Hauschild, A.; Long, G.V.; Sun, P.; McDowell, D.O.; Mookerjee, B.; Robert, C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S682 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. BRENTUXIMAB VEDOTIN VS PHYSICIAN'S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION. (June 2017) Authors: Kim, Y.H.; Prince, H.M.; Whittaker, S.; Horwitz, S.M.; Duvic, M.; Scarisbrick, J.; Quaglino, P.; Zinzani, P.L.; Wolter, P.; Bechter, O.; Wang, Y.; Palanca‐Wessels, M.C.; Wood, K.W.; Li, M.; Liu, Y.; Lin, H.; Little, M.; Danaee, H.; Trepicchio, W.; Dummer, R. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients. (24th March 2014) Authors: Vanneste, L.; Wolter, P.; Van den Oord, J.J.; Stas, M.; Garmyn, M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 29:Number 1(2015:Jan.) Page Start: 61 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Dabrafenib plus trametinib in BRAF K601E‐mutant melanoma. (1st February 2019) Authors: Rogiers, A.; Thomas, D.; Vander Borght, S.; van den Oord, J.J.; Bechter, O.; Dewaele, M.; Rambow, F.; Marine, J.‐C.; Wolter, P. Journal: British journal of dermatology Issue: Volume 180:Number 2(2019) Page Start: 421 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Dabrafenib plus trametinib in BRAF K601E‐mutant melanoma. (22nd November 2018) Authors: Rogiers, A.; Thomas, D.; Vander Borght, S.; van den Oord, J.J.; Bechter, O.; Dewaele, M.; Rambow, F.; Marine, J.‐C.; Wolter, P. Journal: British journal of dermatology Issue: Volume 180:Number 2(2019) Page Start: 421 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PATIENT‐REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ALCANZA STUDY. (June 2017) Authors: Prince, H.M.; Dummer, R.; Whittaker, S.; Horwitz, S.; Duvic, M.; Scarisbrick, J.; Quaglino, P.; Zinzani, P.L.; Wolter, P.; Sanches, J.; Ortiz‐Romero, P.; Akilov, O.; Geskin, L.; Huen, A.; Wang, Y.; Palanca‐Wessels, M.C.; Richhariya, A.; Feliciano, J.; Zhu, Y.; Lin, H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. RESPONSE BY STAGE IN CD30‐POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY. (June 2017) Authors: Horwitz, S.; Whittaker, S.; Duvic, M.; Dummer, R.; Kim, Y.H.; Scarisbrick, J.; Quaglino, P.; Zinzani, P.; Wolter, P.; Eradat, H.; Sanches, J.; Ortiz‐Romero, P.; Akilov, O.; Trotman, J.; Taylor, K.; Dalle, S.; Weichenthal, M.; Walewski, J.; Fisher, D.; Wang, Y. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 245 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗